Many microbial pathogens rely on a type II fatty acid synthesis (FASII) pathway which is distinct from the type I pathway found in humans. Enoyl-Acyl Carrier Protein Reductase (ENR) is an essential FASII pathway enzyme and the target of a number of antimicrobial drug discovery efforts. The biocide triclosan is established as a potent inhibitor of ENR and has been the starting point for medicinal chemistry studies. We evaluated a series of triclosan analogs for their ability to inhibit the growth of Toxoplasma gondii, a pervasive human pathogen, and its ENR enzyme (TgENR). Several compounds were identified that inhibited TgENR at low nanomolar concentrations, but could not be further differentiated due to the limited dynamic range of the TgENR activity assay. Thus, we adapted a thermal shift assay (TSA) to directly measure the dissociation constant (K d ) of the most potent inhibitors identified in this study as well as inhibitors from previous studies. Furthermore, the TSA allowed us to determine the mode of action of these
INTRODUCTION
Toxoplasma gondii is an obligate intracellular, protozoan parasite that infects about one third of the world's population, causing substantial morbidity and mortality. [1] [2] [3] [4] [5] [6] The life cycle of T. gondii is comprised of a sexual phase that only takes place in the primary host (cats of the Felidae family), and an asexual phase that can occur in any warm-blooded animal, including humans. [7] [8] Currently there is no available vaccine to prevent infection in humans, and only the antifolate medicines sulfadiazine and pyrimethamine are typically used for treatment of T. gondii in humans. 2, 9 Sulfonamides are associated with hypersensitivity, and pyrimethamine with bone marrow toxicity. Even though these medications are effective against tachyzoites, the obligate intracellular form of the parasite in the acute stage of the disease, they are ineffective against the encysted, latent bradyzoites. There is no available treatment to eliminate bradyzoites in humans. 10 T. gondii infection in immunocompetent individuals is generally asymptomatic and self-limiting, whereas in immunocompromised people, T. gondii infection can cause eye and brain disease such as toxoplasmic encephalitis, chorioretinitis and in severe cases can be fatal. [11] [12] Pregnant women are especially at risk because the parasite can be transmitted from mother to fetus, and can lead to congenital toxoplasmosis that may result in abortion, neonatal death, or fetal abnormalities. 2, 9, [13] [14] [15] [16] [17] [18] T. gondii parasites contain a plastid organelle, called the apicoplast, which harbors plant-like metabolic pathways. 19 One pathway that resides in the apicoplast is the machinery for a type II fatty acid synthesis (FASII) pathway which is prokaryotic-like. [20] [21] The FASII pathway in T. gondii has been shown to be essential for parasite survival making it an attractive target for drug discovery efforts. [22] [23] [24] [25] [26] In malaria parasites, a similar FASII pathway is critical for liver stage development [27] [28] and is thought to have an important role in the synthesis of lipoic acid. 29 In contrast to the type II pathway, humans rely on a distinct type I pathway for bulk fatty acid synthesis, which is encoded in a single polypeptide chain. 30 Fatty acid biosynthesis is an iterative process involving the condensation of malonyl-CoA with a nascent fatty acid chain that is covalently bound to Acyl Carrier Protein (ACP). The enzyme Enoyl-ACP Reductase (ENR) is responsible for the final reductive step in each round of fatty acid chain elongation, the NADH-dependent reduction of trans-2-enoyl-ACP to acyl-ACP. 31 Many inhibitors of bacterial and parasitic ENR enzymes have been previously described including diazaborines, isoniazid and triclosan. [32] [33] [34] It has been shown that triclosan inhibits TgENR with an IC 50 value of less than 20 nM in an in vitro inhibition assay using pure recombinant TgENR. 35 Triclosan also inhibits growth of T. gondii parasites with an IC 50 of about 200 nM, presumably due to its inhibition of the FASII pathway. 23 Even though triclosan is a potent inhibitor of TgENR, it has limitations including poor bioavailability and impairment of muscle contractility that prevent it from being a safe and effective medicine. 36 Instead, triclosan has been exploited as a scaffold to generate a series of analogues, many of which are also potent inhibitors of TgENR. 35, [37] [38] [39] In this study, we report the inhibitory properties of a set of 2'-, 4'-, 5-and 6-substituted triclosan analogues developed as inhibitors of Plasmodium falciparum ENR (PfENR) and Mycobacterium tuberculosis ENR (MtInhA). 27, [40] [41] [42] [43] Several of these compounds inhibited TgENR at low nanomolar concentrations, the lowest concentrations that we are able to assess in our enzymatic activity assay. To further characterize the inhibitory properties of these compounds and potent inhibitors from previous medicinal chemistry efforts [37] [38] we employed a thermal shift assay (TSA). Using this assay, we were able to confirm the mode of action for all of the compounds as binding to the TgENR/NAD + complex rather than to the TgENR/NADH complex or to TgENR alone. Combined with thermodynamic parameters determined by differential scanning calorimetry, we calculated dissociation constants [44] [45] [46] for NAD + and NADH binding to TgENR as well as for inhibitor binding to the TgENR/ NAD + complex. The K d values we determined range from 6 mM (for NAD + binding to TgENR) to 6.3 fM (for compound 19 binding to the TgENR/NAD + complex), highlighting the large dynamic range of the TSA. Consequently, TSA results combined with enzyme and parasite inhibition data provide a better basis to differentiate between potent ENR inhibitors.
MATERIALS AND METHODS

Compound Preparation and Synthesis
Compounds were designed and synthesized as described by Alan Kozikowski [37] [38] and Jacobus Pharmaceutical Inc. 27, [40] [41] [42] [43] The purity of compounds 1-4, 43 5-10, 40 [11] [12] [13] [14] [41] [42] 15-18, 27 [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] 38 and 30-32 37 was >95% as determined by HPLC and the identity of each compound was verified by high resolution mass spectrometry. The compounds were initially dissolved in DMSO at a concentration of 10 mM, and further diluted to required concentrations in culture media (described below). For cell proliferation assays the final concentration of DMSO was not more than 0.1%, whereas for the in vitro TgENR enzyme assay the DMSO concentration was 1%.
Parasite and Cell Culture
The strain of T. gondii parasites used in this set of experiments was a modified type I RH strain which expresses yellow florescent protein (RH-YFP), kindly provided by Dr. Boris Striepen (University of Georgia). Parasites were maintained in confluent monolayers of Human Foreskin Fibroblast (HFF) cells at 37 °C and 5% CO 2 in culture medium consisting of Iscove's Modified Dulbecco's Medium supplemented with 10% Fetal Calf Serum, 1% Glutamax, and 1% Penicillin-Streptomycin-Fungizone (Invitrogen).
In vitro Challenge Assay
Growth inhibition of T. gondii was assessed as previously described. 38 Host cells containing RH-YFP parasites were lysed by double passage through a 25g needle, and separated from the parasites by filtration and centrifugation. Confluent monolayers of HFF cells in 96-well plates (Falcon 96 Optilux Flat-bottom) were infected with 3,500 parasites per well. Parasites were allowed to infect host cells for one hour, after which experimental compounds and control solutions were added. Seventy-two hours later, the parasite burden was assessed by measuring relative fluorescence using a Synergy H4 Hybrid Reader (BioTek) and Gen5 1.10 software. All compounds and control solutions were tested in triplicate exemplars. Biological replicates of each experiment were performed twice for compound 17 and three times for all other compounds. The compounds were tested in a dilution series from 10 µM to 0.01 µM concentrations as described previously. 38 In each assay, these results were compared with those for DMSO control and triclosan. Other internal controls included a curve obtained with varying concentrations of parasites to confirm that each assay detected differing numbers of parasites, and cultures treated with a known inhibitory concentration of pyrimethamine and sulfadiazine as a positive control. Inhibitory index was calculated as: [RFU (compound) −RFU (control fibroblasts) ]/[RFU (DMSO control) −RFU (control fibroblasts) ]×100. MIC 50 is defined as the compound concentration required to inhibit replication by 50%.
Human cell proliferation assay
Potential cytotoxic effects of the compounds were assessed using Cell Proliferation Reagent WST-1 (Roche), which measures the metabolic activity of viable cells. Confluent HFF cells in 96-well plates were treated under the same conditions as in the challenge assay described above, except that the cells were not infected with parasites. After 72 hours, the cells were incubated with WST-1 reagent for 1-2 hrs, and cell viability was assessed by measuring the absorbance at 420 nm of the final colored product, which correlates directly with cell number. All samples were tested in triplicate in at least two biological replicates.
Inhibition of TgENR activity in vitro and enzymatic assay
Recombinant TgENR was purified as described previously. 47 A 96-well plate assay was used to measure the inhibition of TgENR as described previously. [37] [38] Briefly, a SpectraMax M2 plate reader was used to monitor the activity of TgENR by consumption of NADH ( 340 = 6220 M −1 cm −1 ). Reactions were carried out in a final volume of 100 µL in 96 well Corning UV plates. A reaction mixture was used containing 100 µM crotonyl-CoA (Sigma), 1 µL of DMSO (or compounds dissolved in DMSO), 5nM TgENR, 100 mM Na/K Phosphate pH 7.5 150 mM NaCl and 100 µM NADH. The enzymatic activity was determined by comparing the slopes of the absorbance curves for each well to those of the blanks in the first column of the plate. Each compound was measured in duplicate at 1 µM final concentration. Potent inhibitors (>90% inhibition at 1 µM) were further analyzed to determine IC 50 values in triplicate. Nonlinear regression analysis was performed using GraphPad Prism software.
To calculate the K m and k cat values for NADH and Crotonyl-CoA we followed a method described previously. 25 The K m and k cat were determined at variable concentrations of NADH (0-0.5 mM) in triplicate and a fixed concentration of crotonyl-CoA (100 M). The K m and k cat for Crotonyl-CoA were determined at concentrations ranging from 0.8-150 µM and a fixed concentration of NADH (100µM). Kinetic parameters were calculated by fitting the initial velocity data to the Michaelis-Menten equation using GraphPad Prism software.
Thermal Shift Assay (TSA)
A real-time PCR (RT-PCR) instrument, in the presence of Sypro Orange (an environmentally sensitive fluorescent dye), was used to monitor the thermal unfolding of TgENR alone or in the presence of ligands. The TSA was modified from previous reports [44] [45] [46] to measure the thermal melting temperature (T m ) of TgENR. Real-time PCR tube strips (Eppendorf) were used to hold 31 µL mixtures containing final concentrations of 2 µM TgENR, 20 µM inhibitor and 100 µM cofactor. The reactions were set up with a 28 µl mixture of TgENR and buffer (20 mM HEPES pH 7.5, 100 mM NaCl) to which 1 µL of water (or cofactor dissolved in water), 1 µL DMSO (or inhibitor dissolved in DMSO), and 1 µL of Sypro Orange (Sigma, Product Number S-5692 at a final concentration of 5X) was added. The reaction mixture was incubated in the RT-PCR machine (Applied Biosystems,
Step One Plus Real-Time PCR System) for 2 minutes at 20 °C followed by 0.2 °C increases in the temperature every 10 seconds until a final temperature of 80 °C was reached. During the thermal scan, fluorescence was monitored using a pre-defined TAMRA filter in which an increase in Sypro Orange fluorescence was observed upon thermal denaturation of TgENR. The derivative of the fluorescence curve was used to determine the T m (as seen in Figure 1 ). The initial T m in the absence of ligands, but in the presence of DMSO, served as the baseline temperature (T o ) for determining temperature shifts ( T m ). All measurements were made in triplicate.
Calculation of binding constant (K d )
The T m values obtained in the TSA were used to calculate the dissociation constant (K d ) as described by Mei-Chu Lo and coworkers. 44 The dissociation constant at the melting temperature was calculated using the equation in which T o is the melting temperature of TgENR with no ligands (baseline), T m is the melting temperature of TgENR in complex with one or more ligands, R is the gas constant, H is the enthalpy of protein unfolding, C p is the heat capacity change on protein unfolding, and [L Tm ] is the free ligand concentration at T m . The two thermodynamic parameters ( H and C p ) were measured by Differential Scanning Calorimetry. A temperature scan of 0.33 mg/mL TgENR from 10 to 65 °C at 1 °C/min was monitored using a VP-DSC microcalorimeter (MicroCal). The change in heat capacity ( C pTo ) of 3.8 kcal/K/ mol was estimated from the difference in baselines between the baselines of the denatured and native states. The enthalpy ( H To ) was obtained from the area under the curve yielding a value of 228.7 kcal/mol. The dissociation constant at the melting temperature was normalized to temperature T (37 °C) using the equation which H L(T) is the van't Hoff enthalpy of binding at temperature T, estimated to be −15 kcal/mol. 44, 48 
Molecular Docking
Molecular docking studies were performed using AutoDock 4.2, 49 SwissPDB Viewer 50 and MacroModel version 8.1 (Schrodinger, LLC, New York, NY, 2012) in conjunction with the X-ray crystal structures of T. gondii ENR in complex with inhibitors triclosan (PDB ID: 202S) 51 and benzimidazole (PDB ID: 1LX6) 52 available from the Brookhaven Protein DataBank. A 10 Å radius of the active site was used to dock the synthesized molecules with a grid box margin of 62. All other docking parameters were left as default. The obtained docking poses were analyzed using PyMol.
RESULTS AND DISCUSSION
Parasite inhibition, host cell cytotoxicity, and inhibition of TgENR enzymatic activity A structure-based approach was adopted by Freundlich and colleagues to develop 2'-, 4'-, 5-and 6-substituted triclosan analogues against PfENR and MtInhA. 27, [40] [41] [42] [43] In the present study, we evaluated 18 of these analogues against Toxoplasma gondii. The triclosan analogues were first tested for efficacy against T. gondii tachyzoites in vitro. Triclosan was also included in the assay for a direct comparison. Type 1 RH tachyzoites that express Yellow Fluorescent Protein (RH-YFP) were used, allowing parasite proliferation to be assessed by means of a fluorometric assay, since relative fluorescence is directly correlated with parasite viability. A seventy-two hour end-point was chosen to allow slow acting compounds to take effect. Seven compounds emerged as the most effective inhibitors of T. gondii tachyzoites: 5, 8, 9, 10, 15, 16 and 17 (Table 1) . These compounds demonstrated an efficacy equivalent to triclosan (MIC 50 of 2.8 µM), with MIC 50 values ranging from 1.6-3.5 µM. The compounds were also tested for cytotoxic activity against Human Foreskin Fibroblast host cells and exhibited no cytotoxic effects at the highest concentration tested (10 µM). These results demonstrate that inhibition of parasite growth at lower concentrations did not result from killing the host cells, however, since we did not reach the MIC 50 for inhibition of host cell proliferation, we do not know the overall selectivity of our compounds.
The triclosan analogues were also screened in duplicate at 1 µM for inhibition of TgENR in an in vitro inhibition assay. Those analogues with significant inhibitory activity (>90 % at 1 µM) were subsequently assayed in triplicate to determine their IC 50 values (Table 1) . A total of six analogues were potent inhibitors of TgENR with IC 50 values of less than 23 nM, similar to that of triclosan (15 nM). None of the compounds with 2'-substitutions proved to have significant inhibitory activity. This result is consistent with a lack of potent activity against PfENR. 43 Based on the current crystal structures of TgENR and PfENR bound to triclosan, 51 the 2'-triclosan analogues are unlikely to be effective since added bulk at this position will likely result in severe steric clashes with the NAD + cofactor (see docking results for further details). Potent inhibitors of TgENR with IC 50 values in the low nanomolar range were found with substitutions at the 4'-, 5-, and 6-positions of triclosan. Previous medicinal chemistry efforts targeting TgENR led to the discovery of several potent 4'-triclosan and 5-triclosan analogues. [37] [38] The activities of 6-triclosan analogues have not previously been described against T. gondii. However, as shown in Table 1 , 6-triclosan analogues such as 15 and 17 can be inhibitors of TgENR enzymatic activity and parasite growth.
Thermal Shift Assay (TSA)
Our current study of 18 triclosan analogues yielded six compounds with TgENR IC 50 values in the low nanomolar range (< 23 nM). These IC 50 values are similar to that of triclosan (15 nM) and approach the low nanomolar concentrations of TgENR enzyme used in our activity assay. Because of this we could not determine which of the six compounds is the most potent or how they compare to triclosan with currently available assays. In addition we have 14 inhibitors discovered in previous studies [37] [38] which also inhibit TgENR with IC 50 values lower than 100 nM, making 20 compounds in total. In an attempt to differentiate between these inhibitors, we adapted a thermal shift assay (TSA) [44] [45] [46] to further characterize the binding of the compounds to TgENR.
A significant advantage of TSA over several other biophysical techniques, such as NMR, mass spectrometry or calorimetry, is that it can be done with higher throughput without requiring large amounts of protein. 44-46, 48, 53-55 This method has been previously employed for screening conditions which stabilize proteins; 46, 56-57 K d calculations for proteins with one or two ligands; 44-45, 48, 55 as well as to determine the mode of action of ligand binding. 55 Calculations of K d values by TSA have been favorably compared to measurements done by other biophysical techniques. 44 We used the TSA to measure the melting temperature (T m ) of TgENR alone, in binary complex with NADH or NAD + cofactor, or in a ternary complex with triclosan (or analogues) and NADH or NAD + bound. Using a real time PCR machine to accurately control the temperature, we monitored the thermal denaturation of TgENR in the presence of the environmentally sensitive dye Sypro Orange. The TSA method consists of monitoring the fluorescence of the dye which has a higher quantum yield when it interacts with hydrophobic amino acids exposed upon TgENR unfolding. As shown in Figure 1 32 The K d for NAD + could not be determined for PfENR, except in the presence of triclosan, yielding an artificially low value of 15 µM 58 , whereas the K d of NAD + for EcENR was determined to be 1.8 mM. 32 The kinetic parameters for TgENR were calculated by using the enzymatic activity assay at 11 different concentrations of NADH and Crotonyl-CoA in triplicate, with the highest concentration of 500 µM and dilutions by factors of two for NADH and 0.8-150 µM for Crotonyl-CoA. Figure 2B shows a Michaelis-Menten plot for TgENR with a k cat of 12 s −1 and K m of 20 µM for NADH; for Crotonyl-CoA, k cat is 26 s −1 and K m is 40 µM (Figure 2C) . These values are similar to those of ENR enzymes from the apicomplexan parasites Eimeria tenella and Plasmodium falciparum (Table 2) . 25, [59] [60] Although K m values cannot be equated with dissociation constants, the K m values for NADH are consistent with the 21 µM K d value determined by TSA.
Inhibitor mode of action determined by TSA
The mode of action of ENR inhibition by triclosan has been well studied in several systems, including apicomplexan parasites, plants and bacteria. Triclosan is an uncompetitive inhibitor with respect to NAD + and forms a tight ternary triclosan/NAD + /ENR complex. Consistent with this mechanism of action, we observed a large shift in T m when TgENR was analyzed by TSA in the presence of triclosan and NAD + , but not in the absence of the cofactor ( Figure 1A) . Interestingly, we also observed a small shift in T m when triclosan was added to TgENR in the presence of NADH ( Figure 1A ). Triclosan has an apparent K d value of 186 µM for the TgENR/NADH complex, an affinity that is probably too weak to have physiological significance since this value is 100,000 times larger than the K d of triclosan binding to the TgENR/NAD + complex (1.3 nM at 100 µM NAD + listed in Table 3 ). The apparent weak binding of triclosan to the TgENR/NADH complex is consistent with reports of ternary triclosan/NADH complexes formed by ENR enzymes from E. coli, 61 Haemophilus influenza 62 and Pseudomonas aeruginosa. 63 Potent inhibition of ENR enzymes with triclosan is due to the slow formation of a tight ternary triclosan/NAD + /ENR complex. PfENR is 50% identical to TgENR and serves as a good example of this phenomenon. Triclosan binds to the PfENR/NAD + complex with relatively low affinity (53 nM) followed by the slow (0.055 s −1 forward rate constant) formation of a tight binding complex with an overall inhibition constant of 96 pM. 64 The tight binding complex involves the formation of an -helix over the inhibitor binding site, a feature that was observed in the crystal structure of TgENR co-crystallized with triclosan and NAD + , making it very likely that triclosan inhibits TgENR through the same mechanism as described for other ENR enzymes. 51 The slow kinetics of inhibition appear to be responsible for the artificially high 15 nM IC 50 value of triclosan shown in Table 1 . The IC 50 value approaches the theoretical limit (half of the 5 nM TgENR concentration) when the enzyme is preincubated with triclosan and NAD + allowing the inhibitory complex to form prior to initiating the assay. In the TSA experiments, there is a total incubation time of about 30 minutes from the time the experiment is set up to the time it reaches T m . This allows enough time for triclosan to form the tight ternary complex. To confirm this, we set up TSA experiments as explained in the Methods section, but allowed 2 hours of preincubation. This pre-incubation time did not affect the K d of triclosan for the enzyme (data not shown). To determine the reproducibility of the TSA measurements, we measured the T m in four experiments in triplicates on different days for TgENR alone, in binary complex with NADH and NAD + and in the ternary complex TgENR/NAD + /triclosan. The standard deviation of these measurements was 0.40, 0.56, 0.36 and 0.37 degree Celsius, respectively.
All of our potent inhibitors were also tested by TSA for binding to the TgENR/NAD + complex, the TgENR/NADH complex, or TgENR alone. In all cases, the inhibitors displayed a similar mode of action as that of triclosan, forming a tight complex with TgENR/NAD + . Figure 1B shows the TSA results for 32, a compound that differs significantly from the structure of triclosan, but displays a similar T m shift profile and thus the same mode of action as triclosan, binding exclusively to the TgENR/NAD + complex. As shown in Figure 1 , the presence of 100 µM NAD + alone (orange curves) or 20 µM inhibitor alone (green curves) does not shift the T m of TgENR and thus, the T m observed in the presence of inhibitor and NAD + is due to the formation of the ternary complex.
Effect of NAD + concentration on inhibitor affinity
In TSA experiments we can control the concentration of the cofactors NADH and NAD + . By contrast, in the enzymatic assay NADH is constantly being consumed and NAD + is formed over the course of the reaction. For TSA, we used 100 µM NADH, the concentration used as the starting point in the enzymatic assay. As described above, this concentration is well above the 21 µK d of NADH, ensuring that the majority of TgENR forms a binary TgENR/NADH complex during the TSA experiments. The same is not true for NAD + . In the TSA experiments described above, 100 µM NAD + was used whereas the K d is 6 mM. Under these conditions, the fraction of enzyme found as a binary TgENR/NAD + complex is very small (~1.6%).
We then analyzed the binding of two inhibitors, triclosan and 32, to better understand how NAD + concentration affects the apparent K d values determined by TSA. We determined K d values for both inhibitors at eight concentrations of NAD + ranging from 2.7 µM to 6 mM. As shown in Figure 3A , the apparent K d for these inhibitors decreases as the concentration of NAD + increases, until reaching a plateau while approaching the K d of NAD + (6 mM). The apparent dissociation constant of triclosan ranges from 18 µM (at a NAD + concentration of 2.7 µM) to 20 fM (at a NAD + concentration of 6 mM), despite the fact that NAD + is in stoichiometric excess to TgENR (2 µM) throughout this concentration range. Similarly, the K d values for compound 32 vary from 51 µM to 689 fM over the same range of NAD + concentrations. These results underscore the need to consider cofactor concentration when comparing K d values for uncompetitive inhibitors like triclosan. For example, a K d value of 32 nM was reported for triclosan binding to PfENR 58 which is similar to the value of 1.3 nM listed in Table 3 for TgENR. However, the K d for PfENR was determined with 250 µM NAD + and the equivalent K d value for TgENR is 105 pM. In a similar experiment, we determined the K d values for triclosan and compound 32 at seven concentrations ranging from 450 nM to 333 µM, while keeping [NAD + ] constant at 100 µM. As expected, we found that the K d values for both compounds decrease as we increase the inhibitor concentration ( Figure 3B ).
We determined the K d values for our most potent TgENR inhibitors in the presence of 6 mM NAD + and compared these values with those determined at 100 µM NAD + (Table 3) . The higher NAD + concentration increased the apparent affinity of all of our inhibitors, however, the factor by which the affinity increased was not uniform across the compound series (Table 3 ). The K d of 25 decreased by a factor of 2,300,000 when NAD + concentrations were increased, whereas the K d of 30 only decreased by a factor of 11,000. Even between similar compounds such as 28 and 29 there were differences in the dependence of K d on NAD + concentrations. These differences may reflect the ability of some inhibitors to bind more tightly to TgENR in the absence of NAD + . In the thermodynamic cycle shown in Figure 4A , these inhibitors would have smaller K i values and larger values corresponding to less selectivity between binding to the TgENR/NAD + complex versus TgENR alone.
We did not detect the binding of any inhibitor to TgENR when we used 20 µM inhibitor concentrations, however, K i values could be well above this level. We screened for inhibitor binding at higher concentrations of inhibitor (111 µM and 333 µM) but found that most compounds did not have measureable binding or interfered with the TSA at these concentrations. Compound 29, however, appeared to bind with a dissociation constant (K i ) of 0.8 mM ( Figure 4B ). This value of K i allows us to estimate the parameter if we can measure the affinity of compound 29 for the E•NAD complex ( K i ) shown in Figure 4A . The K d of compound 29 in the presence of 6 mM NAD + is 116 pM (Table 3 ). We can estimate K i using the equation for the binding of uncompetitive inhibitors in which is the observed dissociation constant of the inhibitor at any concentration of NAD + and K NAD is the K d of NAD + . Since the 6 mM concentration of NAD + used in the TSA equals K NAD , this equation reduces to: Similar estimations of K i can be made for all of the compounds with measured K d values at 6 mM NAD + (Table 3 ). The parameter describing the selectivity of compound 29 for the binary complex would then be 7×10 −8 . The parameter is presumably related to the ratio of K d values shown in Table 3 in the sense that both numbers provide an indication of how dependent an inhibitor is on binding to the binary TgENR/NAD + complex. This phenomenon may help to guide the selection of the best inhibitors. The NAD + concentration has been measured in different cell types, including mouse erythrocytes and mammalian cells with values of 368 µM and a range of 300-800 µM, respectively. [65] [66] [67] [68] [69] Although the concentration of NAD + in the apicoplast of T. gondii has not been measured, it is also likely to be well below the 6 mM K d value. Therefore, at any given time, most TgENR molecules will not have NAD + bound. Indeed, the large discrepancy between the MIC 50 values in Table 1 and the extremely tight binding properties of some of the compounds in Table 3 may be an indication that NAD + levels are low in the apicoplast organelle.
Inhibitor affinity to the TgENR/NAD + complex
The twenty compounds that we examined by TSA all had IC 50 values of less than 100 nM in the TgENR enzyme activity assay (Table 3 ). The calculated K d values at the two NAD + concentrations can be used to identify the most potent compounds and how dependent inhibitor binding is on NAD + concentration (Table 3) . A total of six compounds showed K d values of less than 10 nM with 100 µM NAD + , and less than 100 fM with 6 mM NAD + (5, 9, 10, 15, 19 and 27) . From analyzing these compounds, it is clear that tight binding inhibitors can contain small substituents at the 4'-position (as in compound 5), the 5-position (as in compound 19), or the 6-position (as in compound 15). As described previously [37] [38] , bulky substituents at the 4'-and 5-positions are accommodated by the TgENR active site. Compound 27 contains a large isoxazole ring at the 5-position while compounds 9 and 10 contain a benzylamino moiety. The 6-position triclosan analogues have not been described previously for TgENR. We show that modifications at this position are well tolerated as seen for compounds 15 and 17 (see modeling data below).
Overall, three compounds (5, 9 and 19) appear to bind to the TgENR/NAD + complex as well as triclosan or better. These compounds differ, however, in terms of how dependent the dissociation constants are on NAD + concentration. The ratio of K d values determined at low and high NAD + concentrations is 250,000 for compound 19, whereas this ratio is only 30,000 for compound 9 ( Table 3 ). As discussed above, the reduced dependence of compound 9 on NAD + concentration could reflect the ability of this compound to bind weakly to TgENR, adding an additional route to forming the ternary inhibitor/TgENR/NAD + complex. By contrast, compound 19 may be more dependent on binding to a preformed TgENR/NAD + complex. In this sense, compound 9 could prove to be a more exciting scaffold for further modification. Since a variety of substituents are tolerated at the 5-position, these are possible additions that could improve the properties of compound 9. Similarly, small groups such as those found in compounds 15 and 17 could be added to the 6-position.
Inhibitor Modeling
In order to further understand the different binding properties of the various inhibitors studied, molecular modeling was carried out using the TgENR crystal structure and the molecular docking software AutoDock. 49 The least effective triclosan analogues contained modifications on the B-ring at the 2'-position. The close proximity of the NAD + cofactor to this position on the B-ring is likely to cause a significant steric clash upon inhibitor binding ( Figure 5A ). The addition of a 5-methyl-3-carboxamide-isoxazole group to the A-or B-rings of triclosan resulted in a marked difference in their K d values. The presence of this group at the 5-position on the A-ring (compound 27) produced a very potent inhibitor (K d = 33 fM with 6 mM NAD + ), whereas this modification at the 4'-position on the B-ring gave inhibitor 29 with 3,500 fold less affinity (K d = 116 pM with 6 mM NAD + ).
Molecular modeling was used to rationalize this difference in affinity. Modeling in AutoDock suggested that the isoxazole group, and other large substituents [37] [38] can be tolerated within the hydrophobic pocket surrounding the A-ring due to the mobile alpha helix. Conversely, the positioning of this group on the B-ring extends towards the solvent exposed entrance to the binding site, and should be able to accommodate such a substituent. However, sampling the potential ligand conformations in AutoDock exposed a steric clash between the 4'-methylisoxazole of compound 29 and Phe243 (TgENR numbering) due to the rigid nature of the 5-methyl-3-carboxamide-isoxazole group. The addition of a methylene group between the amide and isoxazole ring (compound 28) decreased the K d by about two orders of magnitude, perhaps because the additional flexibility alleviated this steric clash.
The most promising inhibitors discovered to date have a modification at the 6-position on the A-ring. Considering the extra bulk of the nitrile (compound 15) and the hydroxymethyl (compound 17) moieties, the initial steric clash observed between these substituents and Tyr179 must be alleviated through the movement about C . This result is corroborated through further modeling studies whereby the conserved Tyr179 residue can rotate to accommodate the 6-substitutents within the heart of the binding site ( Figure 5B ).
CONCLUSIONS
We evaluated a series of triclosan analogues as inhibitors of Toxoplasma gondii. The 4'-and 5-substituted triclosan analogues are effective inhibitors of parasite growth and TgENR enzymatic activity. Compounds with modifications at the 2'-position did not show inhibitory activity against TgENR due to steric clashes with either the NAD + cofactor or the top of the binding pocket. Modifications in the 6-position were well tolerated and displayed good inhibitory activity against the parasite and the TgENR enzyme. Six compounds which inhibited TgENR with IC 50 values in the low nanomolar range were identified, but could not be further differentiated due to the limited dynamic range of the TgENR activity assay. A thermal shift assay was employed to further characterize these compounds as well as 14 other potent inhibitors from previous studies. [37] [38] All 20 compounds share the same mode of action and form a ternary complex with TgENR and NAD + , but do not bind significantly to the TgENR/NADH complex or to TgENR alone. The apparent K d values for the inhibitors were strongly affected by NAD + concentration and reached a plateau as the NAD + concentration approached the 6 mM K d of NAD + . By comparing the apparent K d values of the inhibitors at low and high NAD + concentrations, we could identify potent compounds which are less dependent on NAD + binding. Ultimately, we were able to identify six compounds which bind to the TgENR/NAD + complex in the low femtomolar range with affinities similar to or exceeding that of triclosan (5, 9, 10, 15, 19 and 27) . Additionally, four of these compounds inhibit the growth of T. gondii parasites with equal or better potency than triclosan (5, 9, 10 and 15) . TSA data combined with enzyme inhibition and parasite growth inhibition data allow for better discrimination between potent ENR inhibitors, and therefore provide an excellent method for better selection of promising lead compounds. Effect of NAD + and inhibitor concentration on the apparent dissociation constant of two TgENR inhibitors. Thermal Shift Assay was used to determine apparent K d values for triclosan (red) and compound 32 (blue) at different concentrations of NAD + and inhibitor.
Abbreviations
A) The apparent dissociation constants reach a plateau as NAD + concentrations approach 6 mM (the K d of NAD + ). B) The apparent dissociation constants decrease as the inhibitor concentration increases to 333 µM, the highest concentration we were able to measure. Error bars represent the standard deviation of triplicate measurements. Thermodynamic cycle for formation of the ternary inhibitor/TgENR/NAD + complex. The parameter describes the selectivity of inhibitor binding for the TgENR/NAD + complex (E•NAD) and the selectivity of NAD + binding to the inhibitor/TgENR complex (E•I). A) The NAD + /triclosan binding pocket of TgENR from a crystal structure (PDB ID: 202S) 51 Ligands NAD + and triclosan are shown in stick format colored by atom type. Modification of the 2' atom (marked with an asterisk) results in decreased affinity (see compounds 1, 2, 3 and 4) due to steric clashes with the NAD + cofactor and the binding pocket. B) Molecular modeling of inhibitor 17 showing the position of the additional OH group and its close proximity to the two fully conserved active site Tyr residues. 
